Ponatinib, the third-generation TKI for CML, targets Src and VEGFR, PDGFR, and FGFR, which are three crucial receptors associated with angiogenesis. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.